Lycia Therapeutics is a biotechnology company using its proprietary lysosomal targeting chimera (LYTAC) platform to discover and develop best-in-class therapeutics that degrade extracellular and membrane-bound proteins. These proteins drive a wide range of difficult-to-treat diseases, including autoimmune and inflammatory conditions. Lycia was established in 2019 in collaboration with academic founder and Nobel Laureate Carolyn Bertozzi, Ph.D., professor of chemistry and HHMI investigator at Stanford University. In June, 2026, Lycia Therapeutics completed a $75 million Series D financing to advance its pipeline of LYTAC extracellular protein degraders into the clinic. Lycia is headquartered in South San Francisco.
Visit https://lyciatx.com/ for more information.
Lycia Therapeutics is seeking a highly motivated and experienced Senior Director, Controller to lead the company’s accounting and financial reporting functions during a pivotal period of growth. Reporting to the SVP, Finance, this leader will own the integrity of Lycia’s financial statements, direct the monthly and quarterly close process, lead the annual audit, and ensure the company’s accounting infrastructure scales with its ambitions. This is a high-visibility role that partners closely with senior leadership and the audit committee on complex accounting matters and cross-functional financial operations.